This study assessed ANA prevalence and its association with outcomes in AF patients.<h4>Methods</h4>In a cohort of 240 AF patients on anticoagulant therapy (median age 69, median CHA2DS2-VASc = 4), without any ANA-related autoimmune diseases, we determined ANA (positive if > 20 ELISA units [EU]) along with antiphospholipid antibodies in accordance to ACR/EULAR (ACR/EULAR-aPL). This evidence concerns the gene BTG3 and atrial fibrillation.